Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drop showdown: which works best for dry eye during cataract surgery?

NCT ID NCT07397949

Symptom relief Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common eye drops—rebamipide and diquafosol—for managing dry eye in people having cataract surgery. Sixty adults with mild to moderate dry eye will use one of the drops four times a day, starting one month before surgery and continuing for three months after. Researchers will check tear film stability and dry eye symptoms to see if one treatment is as good as the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rebamipide 2% ophthalmic solution and Diquafosol 3% ophthalmic solution
What this could lead to
If one eye drop is shown to be as effective as the other, doctors may have more options to manage dry eye around cataract surgery, improving comfort and vision outcomes.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. There is also a chance neither treatment proves clearly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40 years or older scheduled for unilateral cataract surgery * Presence of dry eye disease, defined by an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following: * Tear film breakup time (TBUT) ≤7 seconds * Oxford corneal staining grade ≥1 * Schirmer's test value ≤10 mm/5 minutes * Ability and willingness to comply with the study protocol and follow-up schedule * Provision of written informed consent Exclusion Criteria: * Active ocular infection or inflammation, including infectious keratitis * History of ocular surgery other than cataract surgery in the study eye * Use of topical medications that may affect the ocular surface (e.g., intraocular pressure-lowering eye drops) * Any ocular or systemic condition judged by the investigator to interfere with study participation or outcome assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Dry eye disease (DED)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung Mec

    Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.